John
Your data is a worrying. We use the Roche method and perform
well on EQAS but I have just had a look at the values that we get for the
scheme and can see that the lowest values are usually around 0.7mmol/L whereas
the problems seem to be most exaggerated at less than 0.4mmol/L.
There is a strong argument for EQAS schemes to include extremely
low values from time to time to test out this issue.
Regards
Graham
From: Clinical biochemistry discussion list
[mailto:[log in to unmask]] On Behalf Of Sale, John
Sent: 02 November 2009 12:00
To: [log in to unmask]
Subject: Two Roche issues
We should be
most grateful for any comments that Roche users, or others, may have on two
issues that have arisen in our laboratory.
1) HDL
Cholesterol
In January we
changed our main analytical platform from Olympus to Roche (cobas 6000), and
initial evaluation data for the new HDL cholesterol method was acceptable
(Roche = 1.04*Olympus - 0.08). However, we have now become aware of a small
subset of patients with HDL values toward the lower end of the range whose
results are significantly lower when measured by the Roche method. Comparison
of the first 9 months of Roche data with the previous 9 months of Olympus results
showed overall distributions of cholesterol and HDL that were virtually
identical, but there were many more very low (<0.15 mmol/L) HDLs in
the Roche group and the number of total:HDL cholesterol ratios greater
than 10 was four times higher:
Median data
(results in mmol/l):
|
Lipids |
Chol |
Trig |
LDL |
HDL |
Ratio |
Ratio >10 |
Roche |
30217 |
4.9 |
1.4 |
2.7 |
1.32 |
3.6 |
77 |
Olympus |
35115 |
4.9 |
1.4 |
2.7 |
1.35 |
3.6 |
18 |
|
Olympus |
Roche |
Lowest HDL |
0.23 |
0.09 |
Highest
Chol/HDL ratio |
16.5 |
47.3 |
An example of
serial results for an actual patient is shown below, where the last set was
obtained using Roche reagents:
Date\Time CHO
TRIG HDL LDL CHO/HDL
180805 0835 4.8
2.8 0.42 3.1 11.4 Olympus
230206 1230
4.9 3.7 0.32 2.9
15.3 “
040507 1000
4.8 3.9 0.37 2.7
13.0 “
231107 0920
3.8 3.0 0.42
2.0 9.0 “
171108 0910 4.8
10.2 0.51 NA
9.4 “
230909 0900 5.2
2.5 0.15 3.9 34.7 Roche
Also results
for 2 samples comparing results obtained by Roche methods with those from a
different analyser in a neighbouring laboratory:
CHO
TRIG HDL LDL CHO/HDL
Sample 1 Roche
4.6 2.3 0.30 3.3
15.3
Sample 1 Other
4.6 2.6 0.64 2.8
7.2
Sample 2 Roche
3.5 3.9 0.11 1.6
31.8
Sample 2 Other
3.5 4.1 0.30
1.3 11.7
Have any
other Roche users noted this problem, and if so do you have an explanation or
work around for it?
2)
Magnesium
Earlier this
year Roche circulated a Product Alert Notice for cobas systems requiring
adjustment of C.f.a.s set point for magnesium. This re-standardisation was
necessary due to deviation of the master-lot set point to atomic absorption
spectrophotometry, the correction being in the order of minus 10%. Currently
the mean of the Roche chlorophosphoazo III dye method group is close to the all
method mean for magnesium in the UKNEQAS EQA program, although this scheme does
not report any results for atomic absorption methods. A reduction of 10% would
put the Roche group out of line with other scheme participants.
Have other
Roche users independently verified the need for this change, and is it
justified by the method’s performance in other (non UK?) EQA schemes?
Many thanks
John Sale
Dr
J K Sale
Principal
Clinical Scientist
Clinical
Biochemistry Department
Poole
Hospital NHS Foundation Trust
Tel:
+44 1202 448067
Dr
J K Sale
Principal
Clinical Scientist
Clinical
Biochemistry Department
Poole
Hospital NHS Foundation Trust
Tel:
01202 448067
------ACB discussion List Information-------- This is an
open discussion list for the academic and clinical community working in
clinical biochemistry. Please note, archived messages are public and can be
viewed via the internet. Views expressed are those of the individual and they
are responsible for all message content. ACB Web Site http://www.acb.org.uk
List Archives http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List
Instructions (How to leave etc.) http://www.jiscmail.ac.uk/
Cymraeg:-
Mae'r neges hon yn
gyfrinachol.Os nad chi yw'r derbynnydd y bwriedid y neges ar ei gyfer, byddwch
mor garedig â rhoi gwybod i'r anfonydd yn ddioed. Dylid ystyried un rhywd
datganiadau neu sylwadau a wneir uchod yn rhai personol,ac nid o angen rhaid yn
rhai o eiddo Bwrdd Iechyd Prifysgol Abertawe Bro Morgannwg, nac unrhyw ran
gyfansoddol ohoni na chorff cysylltiedig.
Cofiwch fod yn ymwybodol ei bod
yn bosibl y bydd disgwyl i Bwrdd Iechyd Prifysgol Abertawe Bro Morgannwg roi
cyhoeddusrwydd i gynnwys unrhyw ebost neu o hebiaeth a dderbynnir, yn unol ag
amodau'r Ddeddf Rhyddid Gwybodaeth 2000. I gael mwy o wybodaeth am Ryddid
Gwybodaeth, cofiwch gyfeirio at wefan Bwrdd Iechyd Prifysgol Abertawe Bro
Morgannwg ar www.abm.wales.nhs.uk
English:-
This message is
confidential. If you are not the intended recipient of the message then please
notify the sender immediately. Any of the statements or comments made above
should be regarded as personal and not necessarily those of Bro Morgannwg
University Health Board, any constituent part or connected
body.
Please be aware that, under the
terms of the Freedom of Information Act 2000, Abertawe Bro Morgannwg
University Health Board may be required to make public the content of any
emails or correspondence received. For further information on Freedom of
Information, please refer to the Abertawe Bro Morgannwg University Health
Board website at www.abm.wales.nhs.uk